Important security information
0.6 mg colchicine capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-GP and CYP3A4. One of these dual inhibitors, or a combination of drugs that inhibit P-GP or CYP3A4 with colchicine, can cause fatal or fatal colchicine poisoning. Mitigare should not be used in patients with renal and hepatic impairment. The safety and efficacy of mitigare for acute treatment of gout eruption during immunization have not been studied. Mitigare is not an analgesic medicine and should not be used to treat pain from other causes.
Malignant colchicine overdose has been reported in adults and children. Keep Mitigare away from children. Blood dyslexia such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, aplastic anemia have been reported with colochisin use. Monitor for poisoning and, if present, consider suspension or discontinuation of colchicine.